Yongqian Shu

11PUBLICATIONS
51CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 26, 2025
Integration of multiple machine learning approaches develops a gene mutation-based classifier for accurate immunotherapy outcomes.

Run Shi, Jing Sun, Zhaokai Zhou

|Nov 28, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Caicun Zhou, Gongyan Chen, Yunchao Huang

|Jun 15, 2024
NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity.

Duo Xu, Shiyuan Yin, Yongqian Shu

|Oct 11, 2023
Cancer-derived non-coding RNAs endow tumor microenvironment with immunosuppressive properties.

Tong Hu, Run Shi, Yunru Gu

|Jul 14, 2023
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.

Tao Jiang, Qiqi Jin, Jiahao Wang

|Nov 07, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).

Yuankai Shi, Lin Wu, Xinmin Yu

Pageof 2

Frequent Collaborators

2 joint publications

Yuankai Shi

2 joint publications

Jian Fang

2 joint publications

Caicun Zhou

2 joint publications

Caicun Zhou